Ontology highlight
ABSTRACT: Background
Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and second-line treatments for rheumatoid arthritis (RA) patients. However, their high cost poses a massive burden on healthcare systems worldwide. The expiration of patents for these biologics has driven the production of biosimilar drugs, which are potentially less costly and remarkably similar, albeit not identical to the reference molecules. This paper aims to outline the protocol of a systematic review that will investigate the efficacy and safety profile of biosimilars compared to biologics (objective 1) and the impact of switching between biosimilar drugs and reference biologics on the management of RA patients (objective 2).Methods
We will investigate the effects of a
SUBMITTER: Ascef BO
PROVIDER: S-EPMC8286602 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature